GEA Process Engineering A/S - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GEA Process Engineering A/S

Improve drug properties and production with spray drying

Spray drying is a technique preferred by a growing number of pharmaceutical companies to produce better drugs. This ultra-fast and gentle drying technology offers unique possibilities of producing powders with advanced properties - even under aseptic conditions.

Several companies are already benefitting from the technology as an ‘enabling technology’ - to improve the performance of poorly soluble APIs by producing an amorphous solid dispersion, to obtain controlled release or taste-masking, or to produce advanced powders with specific properties.

GEA Process Engineering - the company behind GEA Niro spray drying technology - is the leading provider of spray drying technology to the pharmaceutical industry, and is one of the few companies that offer a full range of spray drying units and services to companies working with the develop-ment of spray dried pharmaceuticals and pharmaceutical grade products. Our portfolio covers the complete development cycle - from the initial proof of concept tests where only a few milliliters of material are available to full-scale production of clinical trial materials and commercial products under cGMP conditions. For better results on any scale, look to GEA Process Engineering.

Website: www.niro.com
E-mail: gea-niro.pharma@gea.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here